Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2009

View Archived Issues

Tufts College presents new proteasome inhibitors potentially useful for treatment of cancer

IntraCellular Therapies describes new norepirephrine/serotonin transporter inhibitors

GlaxoSmithKline assesses safety and reactogenicity of HIV vaccine 732461

Emergent BioSolutions evaluates safety and pharmacokinetics of anthrax immune globulin

First human study of TUTI-16 in HIV-infected subjects initiated by Thymon, LLC

Novel orally active quinoline derivative potently and selectively inhibits CETP

Cancer vaccine vectors based on adenoviruses from chimpanzees overcome immunity in vivo

New GPR119 receptor agonists for treating diabetes reported in recent Bristol-Myers Squibb patent

Roche imparts novel antidiabetic 11beta-HSD1 inhibitors

Amgen discloses novel CaSR ligands for treating hyperparathyroidism and other conditions

Chemokine CXCR4 receptor antagonists under development at Pharis Biotec

Epigenomics and Quest sign nonexclusive licensing agreement for mGSTP1 DNA biomarker

Novel protein kinase B inhibitors and their use in cancer therapy reported by Amgen

DeveloGen reports positive phase I results for DG-3173

Toray begins clinical trial of PEG-interferon beta in Japan

ImmunoVaccine signs agreement with NIH for its DepoVax vaccine enhancement system

ExonHit reports advances in the clinical development of EHT-0202 for AD

Final results presented for PROPEL pralatrexate trial in T-cell lymphoma

Neuroprotection seen with MP-124 in models of ischemia

NIH awards phase I grant to Oligomerix for biomarker assays in AD

Abbott successfully completes tender offer for Advanced Medical Optics

FDA approves Genzyme's Synvisc-One single injection OA treatment

Eisai and Teikoku Seiyaku sign option and license agreement for donepezil

EMEA halts European Commission decision process on Basilea's Zevtera

The Medicines Company completes tender offer for shares of Targanta